Perpetual Adaptive Trial
Randomization Ratio 3:1; Shared Placebo
Open Label Extension offered

Regimen A (n=160 for each regimen)
Regimen B
Regimen C
Regimen D

3:1 Randomization within each Regimen

Zilucoplan
Verdiperstat
CNM-Au8
Pridopidine

(3:1 active:placebo)

24 weeks on investigational product

Shared Placebo

Screening

as of 3/18/21
How to Find a Center Near You

48 sites are actively enrolling

Contact Info of Participating Sites by State

https://www.massgeneral.org/neurology/als/research/platform-trial-sites

as of 3/18/21
List of enrolling sites as of March 18, 2021
48 sites are enrolling

- Texas Neurology
- Mass General Hospital
- UTHSCSA
- Hospital for Special Care
- Holy Cross Hospital
- Thomas Jefferson
- Houston Methodist
- Henry Ford Health System
- Barrow Neurological Institute
- Ohio State University
- Northwestern University
- University of Chicago
- Wake Forest
- University of Nebraska
- Loma Linda University
- University of Washington
- University of Iowa
- Washington University
- University of Pennsylvania
- University of Michigan
- California Pacific Medical Center
- Penn State Hershey
- UMass Worcester
- University of Miami
- University of Colorado
- Cedars-Sinai
- University of Florida
- University of South Florida
- Columbia University
- University of Virginia
- Emory University
- University of Maryland
- SUNY Upstate
- Beth Israel Deaconess
- Temple University
- Dartmouth-Hitchcock
- Medical College of Wisconsin
- Spectrum Health
- University of Missouri
- University of Minnesota
- Johns Hopkins University
- University of CA Irvine
- University of Kansas
- Vanderbilt University
- University of Kentucky
- Mayo Rochester
- Duke University
- Neurology Associates
Enrollment Updates

NEWS | MAR 9 | 2021

Healey Center for ALS Passes 50% Participant Enrollment Milestone for First 3 Regimens in the HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial, an initiative led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and conducted at sites of the Northeast ALS (NEALS) consortium, continues to gain momentum just months after launching in 2020, passing the 50% participant enrollment milestone for the first 3 regimens.
Patient Navigator

Catherine Small
Allison Bulat
Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

To see whether you might qualify, view the list of eligibility criteria online:
For More Updates

• **Weekly webinars**
  The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

• **Find the schedule and registration links on our website**
  https://www.massgeneral.org/neurology/als/research/platform-trial-news/

**Previously: Drug mechanism of action and science webinars**

- **Jan 21**- Prilenia/Pridopidine  (view recording- https://bit.ly/3ad3qel)
- **Feb 18**- Biohaven/Verdiperstat (view recording- https://bit.ly/301qdDR)